Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
Cognitive/Functional Effects · Metastatic Cancer · Neurotoxicity · Radiation Toxicity · Unspecified Adult Solid Tumor, Protocol Specific
Bottom Line
View on ClinicalTrials.gov: NCT01372774 ↗Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- stereotactic radiosurgery (Radiation); whole-brain radiation therapy (Radiation)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Alliance for Clinical Trials in Oncology
- Primary completion
- Aug 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT |
3.0; 3.7 | <0.0001 sig |
| PRIMARY Overall Survival |
11.6; 12.2 | 0.70 |
| SECONDARY Local Control of the Surgical Bed |
87.1; 80.4 | 0.00068 sig |
| SECONDARY Time to CNS Failure in These Patients |
27.5; 6.4 | — |
| SECONDARY Change in Quality-of-life at 6 Months |
4; 6; 24; 33; 17; 12 | 0.31 |
Summary
Eligibility Criteria
Pre-registration Inclusion Criteria:
- Number of Brain Metastases - Four or fewer brain metastases (as defined on the pre-operative MRI or CT brain scan) and status post resection of one of the lesions.
- Non-CNS Primary Site - Pathology from the resected brain metastasis must be consistent with a non-central nervous system primary site. Note: Patients with or without active disease outside the nervous system are eligible (including patients with unknown primaries), as long as the pathology from the brain is consistent with a non-central nervous system primary site.
- Size of Metastases - Any unresected lesions must measure < 3.0 cm in maximal extent on the contrasted MRI or CT brain scan obtained ≤ 35 days prior to pre-registration. The unresected lesions will be treated with SRS as outlined in the treatment section of the protocol. Note: The metastases size restriction does not apply to the resected brain metastasis; with resected brain metastases only surgical cavity size determines eligibility.
- Size of Resection Cavity - Resection cavity must measure <5.0 cm in maximal extent on the post-operative MRI or CT brain scan obtained ≤35 days prior to pre-registration.
Note: It is permissible for the resection of a dominant brain metastasis to include a smaller "satellite" metastasis as long as the single resection cavity is less than the maximum size requirements.
- Tumor Staging Procedures - All standard tumor-staging procedures necessary to define baseline extra cranial disease status completed ≤42 days prior to pre-registration.
- Treatment with Gamma Knife or Radiosurgery - Able to be treated with either a gamma knife or a linear accelerator-based radiosurgery system.
- Age ≥ 18 years
- Neurocognitive Testing - Willing and able to complete neurocognitive testing without assistance from family and companions. Note: Because neurocognitive testing is one of the primary goals of this study, patients must be able to utilize English language booklets (and/or French booklets if enrolled in Canada).
- Quality of Life (QOL) Questionnaires - Willing and able to complete QOL by themselves or with assistance
- ECOG Performance Status - ECOG Performance Status (PS) 0, 1, or 2.
- SRS Credentialed by IROC Houston Quality Assurance - The site's SRS facility is IROC Houston Quality Assurance approved.
- Neurocognitive Testing Credentialing - The site study team member performing neurocognitive testing of patients must have credentialing confirming completion of the neurocognitive testing training of the protocol.
- Written Informed Consent - Provide written informed consent
- Mandatory Samples for Correlative Tests - Willing to provide mandatory blood and urine samples for correlative research purposes.
Pre-registration Exclusion Criteria:
- Pregnancy, Nursing and Contraception - pregnant women, nursing women and men or women of childbearing potential who are unwilling to employ adequate contraception throughout the study and for men for up to 3 months after completing treatment.
- Prior Cranial Radiation Therapy
- MRI or CT Scans - Inability to complete a MRI or CT scan with contrast of the head.
- Gadolinium Allergy - Known allergy to gadolinium.
- Cytotoxic Chemotherapy - Planned cytotoxic chemotherapy during the SRS or WBRT.
- Other Tumor Types - Primary germ cell tumor, small cell carcinoma, or lymphoma
- Leptomeningeal Metastasis - Widespread definitive leptomeningeal metastasis
- Location of Brain Metastasis - A brain metastasis that is located ≤ 5 mm of the optic chiasm or within the brainstem.
Randomization Inclusion Criteria:
- Number of Unresected Lesions - Post-operative MRI or CT scan confirmed zero, one, two or three unresected lesions.
1.1 Each unresected lesion must measure ≤ 3.0 cm in maximal extent on the contrasted post-operative MRI or CT brain scan.
1.2 Note: The pre-registration, post-operative, brain scan may be used for the randomization scan if obtained ≤ 28 days prior to randomi
Data sourced from ClinicalTrials.gov (NCT01372774). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.